Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GMED
GMED logo

GMED Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
88.510
Open
88.510
VWAP
87.10
Vol
972.53K
Mkt Cap
11.72B
Low
86.130
Amount
84.70M
EV/EBITDA(TTM)
13.88
Total Shares
135.25M
EV
11.32B
EV/OCF(TTM)
15.02
P/S(TTM)
4.10
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
Show More

Events Timeline

(ET)
2026-02-24
16:40:00
Globus Medical Reports Q4 Revenue of $826.4M
select
2026-02-24
16:40:00
FY26 Revenue Expected at $3.18B-$3.22B
select

News

NASDAQ.COM
8.5
03-04NASDAQ.COM
Intuitive Surgical Acquires European Distribution Business
  • Acquisition of European Business: Intuitive Surgical has completed the acquisition of distribution businesses from ab medica, Abex, and Excelencia Robótica, enabling direct operations in Italy, Spain, and Portugal, which is expected to enhance the company's competitiveness in the European market.
  • Market Integration and Leadership: Following the acquisition, operations have been integrated into ISRG's European commercial organization, led by Senior Vice President Dirk Barten, aimed at improving customer responsiveness and market adaptability.
  • Surgical System Growth: By the end of 2025, ISRG's installed base of da Vinci surgical systems in Italy, Spain, and Portugal will exceed 470 units, with the Ion platform recently launched in Italy and Spain, indicating ongoing growth potential in the European market.
  • Optimistic Market Outlook: The European surgical robots market is projected to grow from $2.10 billion in 2024 to $5.21 billion by 2031, with a CAGR of 14%, and ISRG is well-positioned to benefit from this growth due to its strong market presence.
Yahoo Finance
5.0
02-27Yahoo Finance
Executive Change: Kelly Huller Appointed
  • Executive Appointment: Kelly Huller has been appointed as Executive Vice President, General Counsel, and Corporate Secretary as of February 25, 2026, indicating a strengthening of the company's leadership in legal and compliance matters aimed at enhancing corporate governance.
  • Strategic Implications: Huller’s appointment reflects the company's commitment to legal compliance and risk management, which is expected to facilitate more effective operations in a complex legal environment, thereby boosting investor confidence.
  • Industry Context: Given the increasingly stringent regulatory landscape, Huller’s extensive experience will provide essential legal support to help the company navigate potential legal challenges and ensure compliance.
  • Future Outlook: Huller’s addition is viewed as part of the company’s strategic transformation, aimed at supporting long-term growth objectives and market competitiveness through a strengthened legal team.
Yahoo Finance
2.0
02-26Yahoo Finance
Dow Futures Decline as Nvidia Shares Retreat Despite Strong Earnings
  • Nvidia Earnings Reaction: Nvidia reported strong earnings and guidance, yet its shares fell in after-hours trading, indicating market concerns over high valuations that could undermine investor confidence.
  • Market Trend Shift: The S&P 500 has regained its position above the 50-day moving average, suggesting a short-term improvement in market sentiment; however, overall market uncertainty remains, necessitating cautious investor strategies.
  • Dow Futures Movement: Dow futures are declining, reflecting investor caution towards tech stocks, particularly following a pullback in shares of leading companies like Nvidia, which may trigger broader market volatility.
  • Investor Strategy Adjustment: As market sentiment shifts, investors may need to reassess their portfolios, especially in light of the unstable performance of tech stocks, seeking more stable investment opportunities.
NASDAQ.COM
9.5
02-25NASDAQ.COM
Globus Medical Reports Strong Q4 and FY 2025 Financial Results
  • Significant Revenue Growth: In Q4 2025, Globus Medical reported worldwide net sales of $826.4 million, a 25.7% increase from $657.3 million in Q4 2024, indicating strong market demand and solidifying its position in the musculoskeletal technology sector.
  • Enhanced Profitability: GAAP net income surged to $140.6 million from $26.5 million year-over-year, with GAAP diluted EPS rising from $0.19 to $1.03, reflecting successful cost control and operational efficiency, which boosts investor confidence.
  • Improved Free Cash Flow: The company achieved free cash flow of $588.8 million in FY 2025, up from $405.2 million in 2024, demonstrating ongoing improvements in capital management and profitability, providing stronger support for future investments and shareholder returns.
  • Optimistic Future Outlook: For FY 2026, revenue is projected between $3.18 billion and $3.22 billion, representing an 8-9% growth compared to 2025, while non-GAAP diluted EPS is expected to range from $4.40 to $4.50, showcasing management's confidence in future growth and market potential.
NASDAQ.COM
9.5
02-25NASDAQ.COM
Globus Medical Reports Strong Q4 2025 Earnings
  • Significant Revenue Growth: Globus Medical reported revenue of $826.42 million for Q4 2025, marking a 25.7% increase year-over-year and surpassing the market expectation of $787.85 million, indicating strong market demand and sales capability.
  • Earnings Per Share Beat: The EPS for the quarter was $1.28, a 52.4% increase from last year's $0.84, and exceeded analyst expectations of $1.06, reflecting a substantial improvement in the company's profitability.
  • Financial Health Metrics: By comparing key metrics with year-ago figures and analyst estimates, investors can more accurately assess the company's financial health, enabling more informed decisions regarding future stock price performance.
  • Optimistic Market Outlook: With the rapid advancement of quantum computing technology, Globus Medical stands to benefit from this technological revolution, potentially driving further innovation and market share growth in the medical device sector.
seekingalpha
9.5
02-25seekingalpha
Globus Medical Reports Record Q4 2025 Earnings and Growth Momentum
  • Significant Revenue Growth: Globus Medical reported Q4 2025 revenue of $826.4 million, a 25.7% increase year-over-year, with non-GAAP EPS reaching $1.28, reflecting a 52.1% rise over Q4 2024, showcasing strong market performance and enhanced profitability.
  • Sustained Spine Business Growth: The U.S. spine business grew by 10% in Q4, marking 48 consecutive weeks of growth, indicating robust development in core business areas and expected further market share gains.
  • Product Innovation Launches: Six new spine products were launched in 2025, with four introduced in Q4, particularly the DuraPro power tools receiving positive feedback from surgeons, enhancing the company's competitive edge in the surgical equipment market.
  • Optimistic 2026 Outlook: The company reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP EPS expectations to $4.40 to $4.50, reflecting management's confidence in sustained profitability and market growth.
Wall Street analysts forecast GMED stock price to rise
13 Analyst Rating
Wall Street analysts forecast GMED stock price to rise
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
87.00
Averages
101.00
High
114.00
Current: 0.000
sliders
Low
87.00
Averages
101.00
High
114.00
Wells Fargo
Overweight
maintain
$98 -> $104
AI Analysis
2026-02-26
Reason
Wells Fargo
Price Target
$98 -> $104
AI Analysis
2026-02-26
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Globus Medical to $104 from $98 and keeps an Overweight rating on the shares following quarterly results. At 33.9% consolidated EBITDA with Nevro still in early innings of margin improvement, the firm sees the path to the mid-30s EBITDA margins as credible.
Truist
Richard Newitter
Buy
maintain
$105 -> $115
2026-02-25
Reason
Truist
Richard Newitter
Price Target
$105 -> $115
2026-02-25
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Globus Medical to $115 from $105 and keeps a Buy rating on the shares. The firm cites the company's "impressive" Q4 earnings beat and expects Globus to continue growing above market in US Core Spine in 2026, which should "more than offset capital lumpiness", the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GMED
Unlock Now

Valuation Metrics

The current forward P/E ratio for Globus Medical Inc (GMED.N) is 21.59, compared to its 5-year average forward P/E of 25.96. For a more detailed relative valuation and DCF analysis to assess Globus Medical Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
25.96
Current PE
21.59
Overvalued PE
32.67
Undervalued PE
19.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
13.18
Current EV/EBITDA
11.69
Overvalued EV/EBITDA
16.94
Undervalued EV/EBITDA
9.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.77
Current PS
3.80
Overvalued PS
6.59
Undervalued PS
2.94

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

long term stock picks
Intellectia · 12 candidates
Market Cap: >= 5.00BRegion: USEps 5yr Cagr: >= 8Debt Equity: <= 1Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 12.0%
Ticker
Name
Market Cap$
top bottom
TXRH logo
TXRH
Texas Roadhouse Inc
11.31B
IESC logo
IESC
IES Holdings Inc
8.58B
MLI logo
MLI
Mueller Industries Inc
12.72B
DECK logo
DECK
Deckers Outdoor Corp
14.80B
GMED logo
GMED
Globus Medical Inc
11.78B
NICE logo
NICE
Nice Ltd
7.58B
what are the best long term stocks to buy
Intellectia · 12 candidates
Market Cap: >= 10.00BRegion: USMarket Cap Category: mega, largeAnalyst Consensus: Strong Buy, Moderate BuyNet Margin: >= 10.00Revenue 5yr Cagr: >= 8Debt Equity: <= 1List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
RDDT logo
RDDT
Reddit Inc
26.68B
GMED logo
GMED
Globus Medical Inc
11.79B
SHOP logo
SHOP
Shopify Inc
146.97B
TTD logo
TTD
Trade Desk Inc
12.48B
DECK logo
DECK
Deckers Outdoor Corp
16.43B
TW logo
TW
Tradeweb Markets Inc
26.72B
Stocks for long term investment
Intellectia · 20 candidates
Market Cap: >= 10.00BMarket Cap Category: large, megaRevenue 5yr Cagr: 5 - 1,000Debt Equity: 0 - 1List Exchange: XNYS, XNASReturn On Equity: 10.0% - 1000.0%
Ticker
Name
Market Cap$
top bottom
MNST logo
MNST
Monster Beverage Corp
79.88B
WPM logo
WPM
Wheaton Precious Metals Corp
61.92B
FNV logo
FNV
Franco-Nevada Corp
45.51B
WSM logo
WSM
Williams-Sonoma Inc
25.90B
TW logo
TW
Tradeweb Markets Inc
24.14B
TPL logo
TPL
Texas Pacific Land Corp
23.59B
good for long term investment
Intellectia · 9 candidates
Sector: Healthcare, Healthcare Services & Equipment, Real EstateRegion: USAnalyst Consensus: Strong Buy, Moderate BuyNet Margin: >= 0.00Revenue 5yr Cagr: >= 5Debt Equity: <= 2List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
BEKE logo
BEKE
Ke Holdings Inc
21.88B
UTHR logo
UTHR
United Therapeutics Corp
20.21B
INCY logo
INCY
Incyte Corp
19.65B
PEN logo
PEN
Penumbra Inc
14.05B
GMED logo
GMED
Globus Medical Inc
12.14B
VCEL logo
VCEL
Vericel Corp
1.82B
en español
Intellectia · 10 candidates
Price: <= $173.00Beta: LowRiskCurrent Ratio: >= 1.50Debt Equity: <= 0.500Return On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
MNST logo
MNST
Monster Beverage Corp
79.72B
GMED logo
GMED
Globus Medical Inc
12.60B
NYT logo
NYT
New York Times Co
11.51B
CALM logo
CALM
Cal-Maine Foods Inc
3.79B
COCO logo
COCO
Vita Coco Company Inc
3.05B
COLM logo
COLM
Columbia Sportswear Co
2.89B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B

Whales Holding GMED

M
Madison Avenue Partners, LP
Holding
GMED
+30.98%
3M Return
O
Oberweis Asset Management, Inc.
Holding
GMED
+19.64%
3M Return
L
Leeward Investments, LLC
Holding
GMED
+16.69%
3M Return
V
Vestal Point Capital, LP
Holding
GMED
+6.94%
3M Return
P
Paradice Investment Management Pty Ltd.
Holding
GMED
+6.74%
3M Return
A
Antipodes Partners Ltd.
Holding
GMED
+5.91%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Globus Medical Inc (GMED) stock price today?

The current price of GMED is 86.65 USD — it has decreased -1.32

What is Globus Medical Inc (GMED)'s business?

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.

What is the price predicton of GMED Stock?

Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is101.00 USD with a low forecast of 87.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Globus Medical Inc (GMED)'s revenue for the last quarter?

Globus Medical Inc revenue for the last quarter amounts to 826.42M USD, increased 25.73

What is Globus Medical Inc (GMED)'s earnings per share (EPS) for the last quarter?

Globus Medical Inc. EPS for the last quarter amounts to 1.03 USD, increased 442.11

How many employees does Globus Medical Inc (GMED). have?

Globus Medical Inc (GMED) has 6000 emplpoyees as of March 11 2026.

What is Globus Medical Inc (GMED) market cap?

Today GMED has the market capitalization of 11.72B USD.